A Phase 1/1b first-in-human dose escalation and expansion study for theevaluation of safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of SAR439459 administered intravenously as monotherapy and in combination with REGN2810 in adult
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Sanofi US
Start Date
January 18, 2019
End Date
February 7, 2024
Administered By
Duke Cancer Institute
Awarded By
Sanofi US
Start Date
January 18, 2019
End Date
February 7, 2024